Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.

ABSTRACT:

Background

HER2 mutation has been found to be an oncogenic driver gene in non-small cell lung cancers(NSCLC) and HER2-directed therapies have shown promising results in this unique population, while little is known about its association with outcomes of chemotherapy. The aim of this study was to investigate the efficacy of first line chemotherapy in patients with advanced HER2-mutant lung adenocarcinomas.

Methods

Patients with advanced NSCLC(N = 1714) initially underwent testing for EGFR, KRAS, BRAF mutations and ALK, ROS1 rearrangements, and negative cases were then assessed for HER2 mutations using the method of amplification refractory mutation system(ARMS). The efficacy of first line pemetrexed-based chemotherapy was investigated in patients with HER2-mutant and those wi

SUBMITTER: Wang Y 

PROVIDER: S-EPMC5869778 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature